<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1956">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414241</url>
  </required_header>
  <id_info>
    <org_study_id>202087</org_study_id>
    <secondary_id>20923</secondary_id>
    <nct_id>NCT04414241</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine to Prevent SARS-CoV-2 Infection</brief_title>
  <official_title>Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Peruana Cayetano Heredia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether hydroxychloroquine is an effective
      prophylactic regimen to prevent SARS-CoV-2 infection among healthcare workers. Participants
      will be randomized into two parallel groups. The first arm will evaluate the use of
      hydroxychloroquine every-other-day plus standard measures of protection for the prevention of
      SARS-CoV-2. The second arm will evaluate the use of standard measures of protection for the
      prevention of SARS-CoV-2. The target enrollment is 320 participants. Each study participant
      will be monitored for SARS-CoV-2 seroconversion in weekly visits or for the development of
      COVID-19 symptoms for 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2</measure>
    <time_frame>Eight weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Proportion of participants with grade 3 or more adverse events</measure>
    <time_frame>Eight weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability: Proportion of participants that discontinue prophylactic treatment due to grade 1 or 2 adverse events</measure>
    <time_frame>Eight weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine prophylaxis plus standard measures of personal protection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard measures of personal protection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthcare workers in service during the COVID-19 outbreak including medical, nurse,
             technical, and auxiliary staff.

          2. Negative rapid serologic and molecular testing for SARS-CoV-2.

          3. Written informed consent.

        Exclusion Criteria:

          1. Presents COVID-19 symptoms including cough, fever, myalgias, headaches, loss of smell,
             and taste.

          2. Prior (last 30 days), current or planned use (during study period) of
             hydroxychloroquine, chloroquine sulfate, or azithromycin.

          3. Known cardiac disease or a history of prolonged QT syndrome.

          4. Known allergy or intolerance to hydroxychloroquine and/or chloroquine sulfate.

          5. Use of concomitant medications that are contraindicated with the use of
             hydroxychloroquine.

          6. Other reported medical conditions, such as glucose-6-phosphate dehydrogenase
             deficiency, hepatic or renal insufficiency, or visual acuity or field disturbances,
             that make study participation not in the individual's best interest.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Llanos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Gotuzzo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Max Grogl, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>U.S. Naval Medical Research Unit Six</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia García, MD, MPH, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Espinoza, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Nacional de Salud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alvaro Schwalb, MD</last_name>
    <phone>(+51)988054875</phone>
    <email>alvaro.schwalb@upch.pe</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>César Ugarte-Gil, MD, MSc, PhD</last_name>
    <phone>(+51)997157333</phone>
    <email>cesar.ugarte@upch.pe</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Médico Naval &quot;Cirujano Mayor Santiago Távara&quot;</name>
      <address>
        <city>Callao</city>
        <zip>07006</zip>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosio Guerra, MD, MPH</last_name>
      <email>rosio.guerra@med.navy.mil</email>
    </contact>
    <investigator>
      <last_name>Rosio Guerra, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Hipólito Unanue</name>
      <address>
        <city>Lima</city>
        <zip>15007</zip>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Alonso Soto, MD, MSc, PhD</last_name>
      <email>sotosolari@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alonso Soto, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Arzobispo Loayza</name>
      <address>
        <city>Lima</city>
        <zip>15082</zip>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Aldo Lucchetti, MD</last_name>
      <email>aldolucchetti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aldo Lucchetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <zip>15102</zip>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando Mejia, MD, MSc</last_name>
      <email>fernando.mejia.c@upch.pe</email>
    </contact>
    <investigator>
      <last_name>Fernando Mejia, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2 infection</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

